Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Triple-negative breast cancer (TNBC) accounts for about 20% of clinical breast cancer. Clinical characteristics include early onset, high malignancy and heterogeneity. There is no effective drug target for TNBC, resulting in poor outcomes, high relapse rate and distant metastasis. So, further research on TNBC pathological features is particularly important. Compared with the solvent-based paclitaxel, albumin-bound paclitaxel (nab-P) demonstrates a stronger therapeutic effect. With albumin nanoparticles as a carrier, nab-P increases the concentration of extra-tumor drugs by passing through the

Trial Details

NCT ID
NCT04137653
Phase
PHASE3
Sponsor
Shengjing Hospital
Status
RECRUITING
Cancer Type
Triple Negative (TNBC) Breast Cancer
Interventions
  • nab-Paclitaxel+carboplatin
  • Paclitaxel+carboplatin
Locations (sample)
  • Shenyang, Liaoning, China|41.79222,123.43278

Key Eligibility Criteria

  • breast cancer is confirmed by the mammography, and the immunohistochemical results of cancer tissues are negative for estrogen receptor, progestero…
  • positive for axillary lymph node metastasis;
  • 18-70 years of age, female;
  • patients have good compliance with the planned treatment, who are volunteer to participate in the study, are willing to be treated with solvent-bas…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Triple Negative (TNBC) Breast Cancer Trials on Trialify →